A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

Singh, Jasvinder A.; Christensen, Robin; Wells, George A.; Suarez-Almazor, Maria E.; Buchbinder, Rachelle; Lopez-Olivo, Maria Angeles; Ghogomu, Elizabeth Tanjong; Tugwell, Peter
November 2009
CMAJ: Canadian Medical Association Journal;11/24/2009, Vol. 181 Issue 11, p787
Academic Journal
Background: We sought to compare the benefits and safety of 6 biologics (abatacept, adalimumab, anakinra, etanercept, infliximab and rituximab) in patients with rheumatoid arthritis. Methods: In this network meta-analysis, we included all completed and updated Cochrane reviews on biologics for rheumatoid arthritis. We included data from all placebo-controlled trials that used standard dosing regimens. The major outcomes were benefit (defined as a 50% improvement in patient- and physician-reported criteria of the American College of Rheumatology [ACR50]) and safety (determined by the number of withdrawals related to adverse events). We used mixed-effects logistic regression to carry out an indirect comparison of the treatment effects between biologics. Results: Compared with placebo, biologics were associated with a clinically important higher ACR50 rate (odds ratio [OR] 3.35, 95% confidence interval [CI] 2.62-4.29) and a number needed to treat for benefit of 4 (95% CI 4-6). However, biologics were associated with more withdrawals related to adverse events (OR 1.39, 95% CI 1.13-1.71), with a number needed to treat for harm of 52 (95% CI 29-152). Anakinra was less effective than all of the other biologics, although this difference was statistically significant only for the comparison with adalimumab (OR 0.45, 95% CI 0.21-0.99) and etanercept (OR 0.34, 95% CI 0.14-0.81). Adalimumab, anakinra and infliximab were more likely than etanercept to lead to withdrawals related to adverse events (adalimumab OR 1.89, 95% CI 1.18-3.04; anakinra OR 2.05, 95% CI 1.27-3.29; and infliximab OR 2.70, 95% CI 1.43-5.26). Interpretation: Given the limitations of indirect comparisons, anakinra was less effective than adalimumab and etanercept, and etanercept was safer than adalimumab, anakinra and infliximab. This summary of the evidence will help physicians and patients to make evidence-based choices about biologics for the treatment of rheumatoid arthritis.


Related Articles

  • OII-A-1. Lee, H.; Yim, D. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP3 

    Background: To develop a disease progression model that describes the time course of ACR-N in RA patients treated with placebo.Methods: Using 536 ACR-N values from 80 placebo-treated RA patients enrolled in a 6-month, randomized, double-blind study of etanercept, conducted in 13 centers, a...

  • Adalimumab/etanercept/infliximab.  // Reactions Weekly;2/28/2009, Issue 1241, p6 

    The article discusses research being done on the onset of psoriasis in patients who received adalimumab, etanercept or infliximab for rheumatoid arthritis. It references a study published in the February 2009 issue of "Annals of the Rheumatic Diseases." Of the 25 patients studied, six of these...

  • Anti-TNF ruling is a victory for people with rheumatoid arthritis.  // Practice Nurse;7/9/2010, Vol. 40 Issue 1, p6 

    The article states that rheumatoid arthritis (RA) patients who failed to respond to previous anti-TNF therapy may be offered other treatments, such as rituximab, adalimumab and etanercept, according to the British National Institute for Health and Clinical Excellence (NICE).

  • Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis. Zhang, Xingming; Liang, Fuxiang; Yin, Xiaoxue; Xiao, Xiaojuan; Shi, Peiyu; Wei, Dang; Yao, Liang; Wang, Qi; Chen, Yaolong // Clinical Rheumatology;Feb2014, Vol. 33 Issue 2, p165 

    The aim of this systematic review and meta-analysis is to assess the efficacy and safety of tofacitinib for the treatment of patients with acute rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drug (DMARD). Randomized controlled trials were...

  • Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis. Furuya, Hidekazu; Kasama, Tsuyoshi; Isozaki, Takeo; Umemura, Masayu; Otsuka, Kumiko; Isojima, Sakiko; Tsukamoto, Hiroyuki; Tokunaga, Takehiro; Yanai, Ryo; Takahashi, Ryo // Journal of Multidisciplinary Healthcare;2013, Vol. 6, p25 

    Rheumatoid arthritis (RA) is a significant cause of work disability and job loss. The resulting economic burden experienced by patients has received considerable research attention. This research assesses the effect of tumor necrosis factor (TNF) antagonists (infliximab, etanercept) on the...

  • Zdravím podmínÄ›ná kvalita života u pacientů s revmatoidní artritidou v průbÄ›hu prvního roku anti-TNF léčby. Závada, J.; Uher, M.; Hejduk, K.; Vencovský, J.; Pavelka, K. // Czech Rheumatology / Ceska Revmatologie;2013, Vol. 21 Issue 3, p123 

    Introduction: Health-related quality of life (HRQOL) is an important indicator of severity of musculoskeletal conditions. SF-36 is a generic patient-reported measure of HRQOL implemented in the follow-up protocol of the ATTRA registry. Our goal was to assess HRQOL (as measured by SF-36 and its...

  • Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis. Hayashi, Masatoshi; Kojima, Toshihisa; Funahashi, Koji; Kato, Daizo; Matsubara, Hiroyuki; Shioura, Tomone; Kanayama, Yasuhide; Hirano, Yuji; Ishiguro, Naoki // Modern Rheumatology (Springer Science & Business Media B.V.);Jun2012, Vol. 22 Issue 3, p363 

    We assessed the effect of total large-joint arthroplasty combined with anti-tumor necrosis factor (TNF) therapy for rheumatoid arthritis (RA). We studied 45 RA patients (age 57.91 ± 12.74 years, RA duration 13.43 ± 8.28 years) who underwent total arthroplasty (35 knees, 19 hips, 3 elbows,...

  • Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure. Wakabayashi, Hiroki; Hasegawa, Masahiro; Nishioka, Yosuke; Minami, Yukari; Nishioka, Kusuki; Sudo, Akihiro // Clinical Rheumatology;Feb2013, Vol. 32 Issue 2, p253 

    The present study retrospectively assessed the efficacy of tocilizumab in patients with rheumatoid arthritis (RA) who failed to respond to treatment with etanercept or infliximab. A retrospective study of 33 RA patients who did not respond to etanercept or infliximab was conducted. Responses of...

  • Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Fuerst, Martin; Möhl, Henrike; Baumgärtel, Kerstin; Rüther, Wolfgang // Rheumatology International;Oct2006, Vol. 26 Issue 12, p1138 

    The aim of this object is to study whether treatment with biological or leflunomide increases the risk of wound-healing complications after elective orthopedic surgery. Between March 2002 and September 2003, 201 patients participated in this study with the following inclusion criteria: (a)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics